Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Evidence for L1-associated DNA rearrangements and negligible L1 retrotransposition in glioblastoma multiforme.

Carreira PE, Ewing AD, Li G, Schauer SN, Upton KR, Fagg AC, Morell S, Kindlova M, Gerdes P, Richardson SR, Li B, Gerhardt DJ, Wang J, Brennan PM, Faulkner GJ.

Mob DNA. 2016 Nov 11;7:21. doi: 10.1186/s13100-016-0076-6. eCollection 2016.

2.

Chromosomal Aberrations in Canine Gliomas Define Candidate Genes and Common Pathways in Dogs and Humans.

Dickinson PJ, York D, Higgins RJ, LeCouteur RA, Joshi N, Bannasch D.

J Neuropathol Exp Neurol. 2016 Jul;75(7):700-10. doi: 10.1093/jnen/nlw042. Epub 2016 May 31.

3.

World Health Organization grade II-III astrocytomas consist of genetically distinct tumor lineages.

Hattori N, Hirose Y, Sasaki H, Nakae S, Hayashi S, Ohba S, Adachi K, Hayashi T, Nishiyama Y, Hasegawa M, Abe M.

Cancer Sci. 2016 Aug;107(8):1159-64. doi: 10.1111/cas.12969. Epub 2016 Jun 22.

4.

Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN-glioblastoma in vivo.

Xu W, Bi Y, Kong J, Zhang J, Wang B, Li K, Tian M, Pan X, Shi B, Gu J, Jiang H, Kong X, Li Z.

Oncotarget. 2016 Apr 26;7(17):24752-65. doi: 10.18632/oncotarget.8407.

5.

Recurrent Glioblastomas Reveal Molecular Subtypes Associated with Mechanistic Implications of Drug-Resistance.

Kwon SM, Kang SH, Park CK, Jung S, Park ES, Lee JS, Kim SH, Woo HG.

PLoS One. 2015 Oct 14;10(10):e0140528. doi: 10.1371/journal.pone.0140528. eCollection 2015.

6.

DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.

Cohen A, Sato M, Aldape K, Mason CC, Alfaro-Munoz K, Heathcock L, South ST, Abegglen LM, Schiffman JD, Colman H.

Acta Neuropathol Commun. 2015 Jun 20;3:34. doi: 10.1186/s40478-015-0213-3.

7.

A robust topology-based algorithm for gene expression profiling.

Seemann L, Shulman J, Gunaratne GH.

ISRN Bioinform. 2012 Nov 11;2012:381023. doi: 10.5402/2012/381023. eCollection 2012.

8.

COE loss-of-function analysis reveals a genetic program underlying maintenance and regeneration of the nervous system in planarians.

Cowles MW, Omuro KC, Stanley BN, Quintanilla CG, Zayas RM.

PLoS Genet. 2014 Oct 30;10(10):e1004746. doi: 10.1371/journal.pgen.1004746. eCollection 2014 Oct.

9.

Mutational profiling of kinases in glioblastoma.

Bleeker FE, Lamba S, Zanon C, Molenaar RJ, Hulsebos TJ, Troost D, van Tilborg AA, Vandertop WP, Leenstra S, van Noorden CJ, Bardelli A.

BMC Cancer. 2014 Sep 26;14:718. doi: 10.1186/1471-2407-14-718.

10.

Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge.

Sturm D, Bender S, Jones DT, Lichter P, Grill J, Becher O, Hawkins C, Majewski J, Jones C, Costello JF, Iavarone A, Aldape K, Brennan CW, Jabado N, Pfister SM.

Nat Rev Cancer. 2014 Feb;14(2):92-107. doi: 10.1038/nrc3655. Review.

11.

Impact of MACC1 on human malignant glioma progression and patients' unfavorable prognosis.

Hagemann C, Fuchs S, Monoranu CM, Herrmann P, Smith J, Hohmann T, Grabiec U, Kessler AF, Dehghani F, Löhr M, Ernestus RI, Vince GH, Stein U.

Neuro Oncol. 2013 Dec;15(12):1696-709. doi: 10.1093/neuonc/not136. Epub 2013 Nov 11.

12.

Network signatures of survival in glioblastoma multiforme.

Patel VN, Gokulrangan G, Chowdhury SA, Chen Y, Sloan AE, Koyutürk M, Barnholtz-Sloan J, Chance MR.

PLoS Comput Biol. 2013;9(9):e1003237. doi: 10.1371/journal.pcbi.1003237. Epub 2013 Sep 19.

13.

Defining a comprehensive verotype using electronic health records for personalized medicine.

Boland MR, Hripcsak G, Shen Y, Chung WK, Weng C.

J Am Med Inform Assoc. 2013 Dec;20(e2):e232-8. doi: 10.1136/amiajnl-2013-001932. Epub 2013 Sep 3.

14.

Glioma stem cells and immunotherapy for the treatment of malignant gliomas.

Toda M.

ISRN Oncol. 2013 May 15;2013:673793. doi: 10.1155/2013/673793. Print 2013.

15.

Leveraging metabolomics to assess the next generation of temozolomide-based therapeutic approaches for glioblastomas.

St-Coeur PD, Touaibia M, Cuperlovic-Culf M, Morin P Jr.

Genomics Proteomics Bioinformatics. 2013 Aug;11(4):199-206. doi: 10.1016/j.gpb.2013.04.003. Epub 2013 Jun 1. Review.

16.

A fourteen gene GBM prognostic signature identifies association of immune response pathway and mesenchymal subtype with high risk group.

Arimappamagan A, Somasundaram K, Thennarasu K, Peddagangannagari S, Srinivasan H, Shailaja BC, Samuel C, Patric IR, Shukla S, Thota B, Prasanna KV, Pandey P, Balasubramaniam A, Santosh V, Chandramouli BA, Hegde AS, Kondaiah P, Sathyanarayana Rao MR.

PLoS One. 2013 Apr 30;8(4):e62042. doi: 10.1371/journal.pone.0062042. Print 2013.

17.

Ionizing radiation in glioblastoma initiating cells.

Rivera M, Sukhdeo K, Yu J.

Front Oncol. 2013 Apr 8;3:74. doi: 10.3389/fonc.2013.00074. eCollection 2013.

18.

Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis.

Kim YW, Koul D, Kim SH, Lucio-Eterovic AK, Freire PR, Yao J, Wang J, Almeida JS, Aldape K, Yung WK.

Neuro Oncol. 2013 Jul;15(7):829-39. doi: 10.1093/neuonc/not024. Epub 2013 Mar 15.

19.

Delineating the cytogenomic and epigenomic landscapes of glioma stem cell lines.

Baronchelli S, Bentivegna A, Redaelli S, Riva G, Butta V, Paoletta L, Isimbaldi G, Miozzo M, Tabano S, Daga A, Marubbi D, Cattaneo M, Biunno I, Dalprà L.

PLoS One. 2013;8(2):e57462. doi: 10.1371/journal.pone.0057462. Epub 2013 Feb 28.

20.

Targeted tissue proteomic analysis of human astrocytomas.

Fang X, Wang C, Balgley BM, Zhao K, Wang W, He F, Weil RJ, Lee CS.

J Proteome Res. 2012 Aug 3;11(8):3937-46. doi: 10.1021/pr300303t. Epub 2012 Jul 25.

Supplemental Content

Support Center